These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 30600480)

  • 21. Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection.
    Gehring AJ; Protzer U
    Gastroenterology; 2019 Jan; 156(2):325-337. PubMed ID: 30367834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection.
    Fisicaro P; Valdatta C; Boni C; Massari M; Mori C; Zerbini A; Orlandini A; Sacchelli L; Missale G; Ferrari C
    Gut; 2009 Jul; 58(7):974-82. PubMed ID: 19201769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A global scientific strategy to cure hepatitis B.
    Revill PA; Chisari FV; Block JM; Dandri M; Gehring AJ; Guo H; Hu J; Kramvis A; Lampertico P; Janssen HLA; Levrero M; Li W; Liang TJ; Lim SG; Lu F; Penicaud MC; Tavis JE; Thimme R; ; ; ; Zoulim F
    Lancet Gastroenterol Hepatol; 2019 Jul; 4(7):545-558. PubMed ID: 30981686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection.
    Franzese O; Kennedy PT; Gehring AJ; Gotto J; Williams R; Maini MK; Bertoletti A
    J Virol; 2005 Mar; 79(6):3322-8. PubMed ID: 15731226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics.
    Chang KM; Liu M
    Curr Opin Pharmacol; 2016 Oct; 30():93-105. PubMed ID: 27570126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4
    Buschow SI; Jansen DTSL
    Cells; 2021 May; 10(5):. PubMed ID: 34066322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of interleukin-21 in HBV infection: friend or foe?
    Li Y; Tang L; Hou J
    Cell Mol Immunol; 2015 May; 12(3):303-8. PubMed ID: 25363528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunopathogenesis of Hepatitis B Virus.
    Tseng TC; Huang LR
    J Infect Dis; 2017 Nov; 216(suppl_8):S765-S770. PubMed ID: 29156047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Alterations of IFN-γ and IL-4 of peripheral blood T cells in patients with chronic HBV infection].
    Li M; Sun X; Zhou Z; Zhang X; Jin S; Gao Y; Gao Y
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Feb; 32(2):240-4. PubMed ID: 26927386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Good and the Bad of Natural Killer Cells in Virus Control: Perspective for Anti-HBV Therapy.
    Fisicaro P; Rossi M; Vecchi A; Acerbi G; Barili V; Laccabue D; Montali I; Zecca A; Penna A; Missale G; Ferrari C; Boni C
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Depletion of CD25+CD4+T cells (Tregs) enhances the HBV-specific CD8+ T cell response primed by DNA immunization.
    Furuichi Y; Tokuyama H; Ueha S; Kurachi M; Moriyasu F; Kakimi K
    World J Gastroenterol; 2005 Jun; 11(24):3772-7. PubMed ID: 15968737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic vaccination against chronic hepatitis B virus infection.
    Michel ML; Mancini-Bourgine M
    J Clin Virol; 2005 Dec; 34 Suppl 1():S108-14. PubMed ID: 16461209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune therapy including dendritic cell based therapy in chronic hepatitis B virus infection.
    Akbar SM; Horiike N; Onji M
    World J Gastroenterol; 2006 May; 12(18):2876-83. PubMed ID: 16718812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
    Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
    Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The molecular basis of the failed immune response in chronic HBV: therapeutic implications.
    Maini MK; Schurich A
    J Hepatol; 2010 Apr; 52(4):616-9. PubMed ID: 20185199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
    Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
    Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.
    Chang JJ; Wightman F; Bartholomeusz A; Ayres A; Kent SJ; Sasadeusz J; Lewin SR
    J Virol; 2005 Mar; 79(5):3038-51. PubMed ID: 15709024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance.
    Lan P; Zhang C; Han Q; Zhang J; Tian Z
    Hepatology; 2013 Jul; 58(1):73-85. PubMed ID: 23447417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
    Martin P; Dubois C; Jacquier E; Dion S; Mancini-Bourgine M; Godon O; Kratzer R; Lelu-Santolaria K; Evlachev A; Meritet JF; Schlesinger Y; Villeval D; Strub JM; Van Dorsselaer A; Marchand JB; Geist M; Brandely R; Findeli A; Boukhebza H; Menguy T; Silvestre N; Michel ML; Inchauspé G
    Gut; 2015 Dec; 64(12):1961-71. PubMed ID: 25429051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies.
    Chen J; Yuan Z
    Virol Sin; 2014 Feb; 29(1):17-24. PubMed ID: 24452540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.